Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled …

ME Wechsler, A Menzies-Gow… - The Lancet …, 2022 - thelancet.com
Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …
被引用次数：114 相关文章

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled …

SOURCE study group - The Lancet Respiratory Medicine, 2022 - yonsei.elsevierpure.com
Background: Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …

[引用][C] Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo …

ME Wechsler, A Menzies-Gow, CE Brightling… - The Lancet Respiratory …, 2022 - cir.nii.ac.jp
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral
corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study …

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled …

ME Wechsler, A Menzies-Gow… - The Lancet …, 2022 - europepmc.org
Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled …

SOURCE study group - The Lancet Respiratory Medicine, 2022 - cuk.elsevierpure.com
Background: Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …

Oral Corticosteroid-Sparing Effect of Tezepelumab in Adults with Severe Asthma

M Wechsler, A Menzies Gow, CE Brightling… - … D007 ADVANCES IN …, 2021 - atsjournals.org
RATIONALE Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin, an epithelial-derived cytokine implicated in asthma pathogenesis …

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled …

ME Wechsler, A Menzies-Gow, CE Brightling… - The Lancet Respiratory …, 2022 - Elsevier
Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled …

ME Wechsler, A Menzies-Gow… - The Lancet …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …

Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled …

SOURCE study group - The Lancet Respiratory …, 2022 - einstein.elsevierpure.com
Background: Tezepelumab is a human monoclonal antibody that blocks the activity of thymic
stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of …